Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

AARD

Aardvark Therapeutics Inc

Feb 12 • 04:00PM ET

12.28

-0.39 -3.08 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 8:07 AMAardvark Therapeutics forms new wholly owned dermatology subsidiary Ardia Therapeutics to develop lead asset DIA-615 and appoints former COO Bryan Jones as Ardia’s chief executive officer.

Held by: VTI IWM VXF IBB VTWO IWO SURI IWN IWC SBIO

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	42.58%	Shs Outstand	21.75M	Perf Week	8.77%
Market Cap	267.38M	Forward P/E	-	EPS next Y	-3.61	Insider Trans	0.50%	Shs Float	12.50M	Perf Month	-20.21%
Enterprise Value	141.58M	PEG	-	EPS next Q	-0.84	Inst Own	27.17%	Short Float	14.20%	Perf Quarter	11.03%
Income	-48.77M	P/S	-	EPS this Y	42.91%	Inst Trans	4.25%	Short Ratio	8.88	Perf Half Y	9.64%
Sales	0.00M	P/B	2.18	EPS next Y	-22.89%	ROA	-44.96%	Short Interest	1.77M	Perf YTD	-6.44%
Book/sh	5.63	P/C	2.12	EPS next 5Y	10.05%	ROE	-48.06%	52W High	19.58 -37.28%	Perf Year	-
Cash/sh	5.80	P/FCF	-	EPS past 3/5Y	-22.31% -	ROIC	-39.82%	52W Low	4.88 151.64%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.38% 8.28%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.30%	Oper. Margin	-	ATR (14)	1.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.03	EPS Q/Q	-283.59%	SMA20	-10.67%	Beta	3.13	Target Price	32.64
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-10.57%	Rel Volume	0.38	Prev Close	12.67
Employees	22	LT Debt/Eq	0.00	Earnings	Nov 13 AMC	SMA200	1.90%	Avg Volume	199.77K	Price	12.28
IPO	Feb 13, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.09% -	Trades		Volume	77,096	Change	-3.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	B. Riley Securities	Buy	$32
Dec-23-25	Initiated	Oppenheimer	Outperform	$35
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy	$47
Nov-07-25	Initiated	BTIG Research	Buy	$26
Sep-29-25	Initiated	Stifel	Buy	$24
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

Today 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-26 08:00AM	Aardvark Therapeutics Announces Leadership Appointments (GlobeNewswire)
08:00AM	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer (GlobeNewswire)
Feb-10-26 08:00AM	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome (GlobeNewswire) -6.45%
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
04:27PM	Loading…
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66% -7.56%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
09:27AM	Loading…
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
04:10PM	Loading…
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Nelson	Chief Financial Officer	Dec 11 '25	Buy	14.40	3,000	43,200	108,484	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Dec 11 '25	Buy	14.48	7,000	101,395	1,551,613	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Oct 15 '25	Option Exercise	4.24	1,229	5,211	1,544,613	Oct 16 06:14 PM
Jones Bryan	Chief Operating Officer	Oct 15 '25	Option Exercise	4.24	1,250	5,300	1,250	Oct 16 06:12 PM
Lee Tien-Li	Chief Executive Officer	Sep 15 '25	Buy	9.66	10,000	96,624	1,543,384	Sep 16 06:15 AM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 15 '25	Proposed Sale	9.02	10,360	93,413		Sep 15 04:05 PM
Lee Tien-Li	Chief Executive Officer	Sep 10 '25	Buy	7.91	9,000	71,212	1,522,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 11 '25	Buy	7.82	6,000	46,926	1,528,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 12 '25	Buy	8.50	5,000	42,516	1,533,384	Sep 12 08:28 PM
Sun Nelson	Chief Financial Officer	Sep 09 '25	Buy	8.07	6,000	48,440	105,484	Sep 10 05:36 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 02 '25	Proposed Sale	8.51	20,000	170,118		Sep 02 04:05 PM
Lee Tien-Li	Chief Executive Officer	Aug 28 '25	Option Exercise	4.24	17,209	72,966	1,513,384	Aug 29 04:05 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Aug 28 '25	Proposed Sale	8.72	27,691	241,565		Aug 28 04:36 PM
Decheng Capital Global Life Sc	10% Owner	Feb 14 '25	Buy	16.00	1,250,000	20,000,000	2,958,887	Feb 19 05:44 PM
Lee Tien-Li	Chief Executive Officer	Feb 14 '25	Buy	16.00	16,542	264,672	1,496,175	Feb 19 04:35 PM
Sun Nelson	Chief Financial Officer	Feb 14 '25	Buy	16.00	10,000	160,000	99,484	Feb 19 04:30 PM
Cormorant Asset Management, LP	Former 10% Owner	Feb 14 '25	Buy	16.00	187,500	3,000,000	987,689	Feb 19 04:02 PM

Open in Screener

CGON

Cg Oncology Inc

Feb 12 • 04:00PM ET

51.62

-1.93 -3.60 %

Healthcare • Biotechnology • USA • NASD

Peers: ONC BPMC EXEL PTCT PBYI FATE KURA MGNX GERN IMMP

| Held by: XBI VTI IWM VB VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.98	Insider Own	37.18%	Shs Outstand	78.28M	Perf Week	4.92%
Market Cap	4.16B	Forward P/E	-	EPS next Y	-2.65	Insider Trans	4.63%	Shs Float	50.68M	Perf Month	-1.83%
Enterprise Value	3.49B	PEG	-	EPS next Q	-0.60	Inst Own	78.09%	Short Float	18.24%	Perf Quarter	32.90%
Income	-151.48M	P/S	1918.89	EPS this Y	-54.31%	Inst Trans	1.69%	Short Ratio	8.64	Perf Half Y	94.87%
Sales	2.17M	P/B	5.88	EPS next Y	-22.00%	ROA	-23.63%	Short Interest	9.24M	Perf YTD	24.33%
Book/sh	8.78	P/C	6.12	EPS next 5Y	-18.19%	ROE	-24.74%	52W High	57.88 -10.82%	Perf Year	84.36%
Cash/sh	8.43	P/FCF	-	EPS past 3/5Y	-61.21% -	ROIC	-21.83%	52W Low	14.80 248.78%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-52.09% -	Gross Margin	-	Volatility	4.32% 5.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1608.74	EPS Y/Y TTM	-85.53%	Oper. Margin	-8285.33%	ATR (14)	2.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.74	Sales Y/Y TTM	217.84%	Profit Margin	-6967.99%	RSI (14)	52.06	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.79	EPS Q/Q	-113.10%	SMA20	-3.04%	Beta	1.32	Target Price	79.86
Payout	-	Debt/Eq	0.01	Sales Q/Q	3774.42%	SMA50	10.21%	Rel Volume	0.75	Prev Close	53.55
Employees	113	LT Debt/Eq	0.01	Earnings	Nov 14 BMO	SMA200	45.24%	Avg Volume	1.07M	Price	51.62
IPO	Jan 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.97% 2704.71%	Trades		Volume	801,669	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Initiated	Wedbush	Outperform	$70
Nov-24-25	Initiated	Truist	Buy
Oct-08-25	Initiated	Guggenheim	Buy	$90
Aug-19-25	Initiated	Piper Sandler	Overweight	$55
Jul-10-25	Resumed	Goldman	Buy	$40
May-02-25	Initiated	JP Morgan	Overweight	$41
Apr-16-25	Initiated	Scotiabank	Sector Perform	$23
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Show Previous Ratings

Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
Jan-09-26 08:30AM	CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC (GlobeNewswire) +29.26%
Jan-06-26 08:00AM	CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
12:20AM	Loading…
Dec-09-25 12:20AM	CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities (Insider Monkey)
Dec-05-25 08:30AM	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Nov-26-25 07:00AM	CG Oncology Announces New Board Member and Board Transition (GlobeNewswire)
Nov-25-25 04:05PM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting (GlobeNewswire)
Nov-17-25 09:26AM	Company News for Nov 17, 2025 (Zacks)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.61%
08:00AM	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-17-25 09:55PM	CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim (Insider Monkey) +5.14%
Oct-16-25 04:33PM	Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene (Insider Monkey)
06:14PM	Loading…
Oct-08-25 06:14PM	Why Cg Oncology Stock Rocketed 7% Higher Today (Motley Fool) +7.13% +9.21%
Sep-22-25 03:19AM	CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment (Insider Monkey)
Sep-19-25 09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-05-25 07:00AM	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months (GlobeNewswire) +6.88%
Sep-03-25 08:00AM	CG Oncology Completes Enrollment in PIVOT-006 (GlobeNewswire)
Aug-29-25 08:00AM	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:14AM	CG Oncology's Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut (Insider Monkey)
12:13AM	H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT (Insider Monkey)
Aug-08-25 08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks) -6.12%
Jul-31-25 11:58AM	CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial (Insider Monkey)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
04:15AM	Loading…
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mulay James	Director	Jan 09 '26	Option Exercise	12.07	11,145	134,515	10,491	Jan 13 04:15 PM
Mulay James	Director	Jan 09 '26	Sale	52.47	11,145	584,799	0	Jan 13 04:15 PM
JAMES MULAY	Director	Jan 09 '26	Proposed Sale	41.93	13,109	549,660		Jan 09 04:32 PM
POST LEONARD E	Director	Nov 17 '25	Option Exercise	0.60	1,000	600	1,000	Nov 18 04:30 PM
POST LEONARD E	Director	Nov 17 '25	Sale	41.43	1,000	41,430	0	Nov 18 04:30 PM
POST LEONARD E	Director	Oct 13 '25	Option Exercise	0.60	1,000	600	1,000	Oct 15 04:15 PM
POST LEONARD E	Director	Oct 13 '25	Sale	43.25	1,000	43,250	0	Oct 15 04:15 PM
Mulay James	Director	Oct 09 '25	Option Exercise	3.72	5,903	21,959	5,903	Oct 10 04:15 PM
Mulay James	Director	Oct 09 '25	Sale	43.99	5,903	259,673	0	Oct 10 04:15 PM
JAMES MULAY	Director	Oct 09 '25	Proposed Sale	40.71	6,557	266,935		Oct 09 04:19 PM
POST LEONARD E	Director	Sep 30 '25	Option Exercise	0.60	5,000	3,000	5,000	Oct 01 05:07 PM
POST LEONARD E	Director	Sep 30 '25	Sale	40.09	5,000	200,450	0	Oct 01 05:07 PM
Mulay James	Director	Sep 29 '25	Option Exercise	1.82	12,755	23,214	12,755	Sep 30 04:38 PM
Mulay James	Director	Sep 29 '25	Sale	39.19	12,755	499,868	0	Sep 30 04:38 PM
LEONARD E POST	Director	Sep 30 '25	Proposed Sale	39.08	5,000	195,400		Sep 30 04:27 PM
Mulay James	Director	Sep 18 '25	Option Exercise	1.82	19,112	34,784	19,112	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Option Exercise	1.82	3,574	6,505	3,574	Sep 22 07:30 AM
Mulay James	Director	Sep 18 '25	Sale	39.01	19,112	745,559	0	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Sale	38.99	3,574	139,350	0	Sep 22 07:30 AM
JAMES MULAY	Director	Sep 18 '25	Proposed Sale	37.72	35,441	1,336,835		Sep 18 04:28 PM
POST LEONARD E	Director	Sep 15 '25	Option Exercise	0.60	1,000	600	1,000	Sep 16 04:15 PM
POST LEONARD E	Director	Sep 15 '25	Sale	35.10	1,000	35,100	0	Sep 16 04:15 PM
LEONARD E POST	Director	Sep 15 '25	Proposed Sale	33.34	3,000	100,020		Sep 15 04:30 PM
Liu Brian Guan-Chyun	Director	Sep 11 '25	Buy	33.00	1,515,151	49,999,983	1,515,151	Sep 15 08:32 AM
Mulay James	Director	Sep 05 '25	Option Exercise	0.60	27,015	16,209	27,015	Sep 08 04:16 PM
Mulay James	Director	Sep 05 '25	Sale	31.53	27,015	851,797	0	Sep 08 04:16 PM
JAMES MULAY	Director	Sep 05 '25	Proposed Sale	30.94	27,015	835,844		Sep 05 04:24 PM
Song Hong Fang	Director	Sep 03 '25	Sale	27.80	100,000	2,779,542	2,903,931	Sep 04 05:00 PM
POST LEONARD E	Director	Sep 03 '25	Option Exercise	0.60	1,000	600	1,000	Sep 04 04:30 PM
POST LEONARD E	Director	Sep 03 '25	Sale	28.00	1,000	28,000	0	Sep 04 04:30 PM
Charming Jade Ltd	Director	Sep 03 '25	Proposed Sale	27.46	100,000	2,746,000		Sep 03 05:06 PM
LEONARD E POST	Director	Sep 03 '25	Proposed Sale	27.46	1,000	27,460		Sep 03 04:29 PM
POST LEONARD E	Director	Jul 17 '25	Option Exercise	0.60	2,000	1,200	2,000	Jul 18 04:30 PM
POST LEONARD E	Director	Jul 17 '25	Sale	28.00	2,000	56,000	0	Jul 18 04:30 PM
LEONARD E POST	Director	Jul 17 '25	Proposed Sale	26.08	2,000	52,160		Jul 17 04:22 PM
POST LEONARD E	Director	May 21 '25	Option Exercise	0.60	1,000	600	1,000	May 22 04:15 PM
POST LEONARD E	Director	May 21 '25	Sale	28.00	1,000	28,000	0	May 22 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Option Exercise	0.60	1,000	600	1,000	Apr 29 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Sale	30.76	1,000	30,760	0	Apr 29 04:15 PM
POST LEONARD E	Director	Mar 17 '25	Option Exercise	0.60	1,000	600	1,000	Mar 18 04:30 PM
POST LEONARD E	Director	Mar 17 '25	Sale	28.00	1,000	28,000	0	Mar 18 04:30 PM
LEONARD E POST	Director	Mar 17 '25	Proposed Sale	27.80	4,000	111,200		Mar 17 04:38 PM
POST LEONARD E	Director	Feb 18 '25	Option Exercise	0.60	1,000	600	1,000	Feb 19 04:15 PM
POST LEONARD E	Director	Feb 18 '25	Sale	28.61	1,000	28,610	0	Feb 19 04:15 PM

AARD

Aardvark Therapeutics Inc

CGON

Cg Oncology Inc

Upgrade your FINVIZ experience